Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Otsuka Holdings Co ( (JP:4578) ) just unveiled an announcement.
Otsuka Holdings Co., Ltd. reported a significant increase in its consolidated financial results for the nine-month period ending September 30, 2025, with a 5.1% rise in revenue and a notable 56.1% increase in operating profit compared to the previous year. The company also announced the inclusion of two new companies, Araris Biotech AG and Otsuka ICU Medical LLC, into its consolidation scope, which may enhance its market position and operational capabilities.
The most recent analyst rating on (JP:4578) stock is a Buy with a Yen9366.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily operating in the pharmaceutical and nutraceutical industries. The company is known for its innovative healthcare products and services, focusing on mental health, oncology, and cardiovascular treatments, as well as functional foods and beverages.
Average Trading Volume: 1,143,983
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen4276.9B
See more data about 4578 stock on TipRanks’ Stock Analysis page.